Mission Statement, Vision, & Core Values (2024) of TG Therapeutics, Inc. (TGTX)

Mission Statement, Vision, & Core Values (2024) of TG Therapeutics, Inc. (TGTX)

US | Healthcare | Biotechnology | NASDAQ

TG Therapeutics, Inc. (TGTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of TG Therapeutics, Inc. (TGTX)

General Summary of TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell mediated diseases, including multiple sclerosis and hematologic malignancies.

Company Detail Information
Headquarters New York, NY
Founded 2010
Primary Focus Oncology and Immunology

Key Products

  • UKONIQ (umbralisib)
  • HEMGENIX (umbralisib in combination with ublituximab)

Financial Performance

As of Q4 2023 financial report:

Financial Metric Amount
Total Revenue $125.4 million
Net Loss ($93.2 million)
Cash and Investments $435.6 million

Market Position

TG Therapeutics is recognized as an emerging leader in B-cell targeted therapies, with significant research and development investments in oncology and immunology treatments.

Research Metric Value
R&D Expenses (2023) $187.3 million
Clinical Trials Active 7 ongoing studies
Patent Portfolio 23 active patents



Mission Statement of TG Therapeutics, Inc. (TGTX)

Mission Statement of TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. focuses on developing and commercializing innovative therapies for hematological malignancies and autoimmune diseases.

Core Components of Mission Statement

Research and Development Focus

TG Therapeutics demonstrates commitment through:

  • $133.64 million spent on R&D in 2022
  • 2 primary drug development platforms
  • Multiple clinical-stage therapeutic candidates
Research Area Active Programs Development Stage
Hematologic Malignancies 3 primary programs Phase 2/3 clinical trials
Autoimmune Diseases 2 primary programs Phase 1/2 clinical trials

Therapeutic Innovation Strategy

Key innovation metrics:

  • 7 active investigational drug candidates
  • 4 FDA breakthrough therapy designations
  • Market capitalization of $379.65 million (as of January 2024)

Patient-Centric Approach

Clinical development statistics:

  • 6 ongoing clinical trials
  • Focused on unmet medical needs
  • Targeting rare disease indications
Disease Category Number of Trials Patient Population
B-cell Malignancies 3 trials Approximately 5,000 patients
Autoimmune Disorders 2 trials Approximately 3,500 patients



Vision Statement of TG Therapeutics, Inc. (TGTX)

Vision Statement: Advancing Innovative Hematology and Oncology Therapies

Strategic Vision Focus Areas
Focus Area Key Objectives
Hematologic Malignancies Develop targeted therapies for B-cell lymphomas and leukemias
Precision Medicine Create personalized treatment approaches
Clinical Development Advance novel therapeutic candidates
Key Therapeutic Pipeline Metrics
  • Total Active Clinical Programs: 4
  • R&D Investment: $102.4 million (2023 fiscal year)
  • Clinical Stage Assets: 3 primary therapeutic candidates

Therapeutic Portfolio Composition

Therapeutic Area Program Status Development Stage
Chronic Lymphocytic Leukemia Umbralisib Development Phase 3 Clinical Trials
Non-Hodgkin Lymphoma Combination Therapy Research Ongoing Clinical Investigations

Research and Innovation Metrics

Patent Portfolio: 47 issued patents globally

Research Collaboration Partnerships: 2 active pharmaceutical collaborations

Financial Investment in Innovation
  • Annual R&D Expenditure: $102.4 million
  • Research Personnel: 78 dedicated scientists
  • Clinical Trial Investments: $64.3 million



Core Values of TG Therapeutics, Inc. (TGTX)

Core Values of TG Therapeutics, Inc. (TGTX) in 2024

Patient-Centric Innovation

TG Therapeutics focuses on developing innovative therapies for patients with challenging medical conditions.

Research Focus Investment in R&D
Hematology/Oncology $156.4 million (2023 annual R&D expenses)
  • Developed umbralisib for B-cell malignancies
  • Ongoing clinical trials in multiple therapeutic areas

Scientific Excellence

Commitment to high-quality scientific research and development.

Scientific Metrics 2024 Data
Active Clinical Trials 7 ongoing clinical programs
Patent Portfolio 23 granted patents

Transparency and Integrity

Maintaining highest standards of corporate governance and ethical conduct.

  • Quarterly financial reporting compliance
  • SEC filing accuracy
  • Independent board oversight
Corporate Governance Details
Independent Board Members 5 out of 8 board members

Collaborative Approach

Strategic partnerships and collaborative research initiatives.

  • Academic research collaborations
  • Pharmaceutical industry partnerships
Collaboration Type Number of Active Partnerships
Research Partnerships 4 active collaborations

DCF model

TG Therapeutics, Inc. (TGTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.